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Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever in East Asia,
which is caused by a novel bunyavirus-SFTSV. Many studies have reported the clinical characters of SFTS patients,
but the reports were not consistent and a systematic summary of clinical manifestations and laboratory parameters
are not available.
Method: A comprehensive literature research of Web of Science, PubMed, Wan Fang Data, and Chinese National
Knowledge Infrastructure databases was conducted on articles which have described the clinical characters of SFTS
patients. Data from selected studies were pooled by using STATA VERSION 12.0 software.
Result: Nine articles comprising 844 laboratory-confirmed SFTSV cases were included in this meta-analysis. The
pooled case fatality rate was 16% (95% CI: 0.13–0.19). The major clinical characters of patients with SFTSV infection
were fever, thrombocytopenia, leucopenia, gastrointestinal symptoms, and central nervous system manifestations.
The risk factors for severe disease included bleeding tendency, central nervous system manifestations, elevated
serum enzymes, and high viral load. Although there is no specific antiviral therapy for SFTSV infection, symptomatic
treatment and supportive therapy including intensive monitoring is the most essential part of case management.
Conclusion: The major clinical characters of patients with SFTSV infection were fever, thrombocytopenia,
leucopenia and gastrointestinal symptoms, and central nervous system manifestations. The risk factors for severity
and fatality among SFTS patients included: old age, CNS manifestations, bleeding tendency, elevated serum
enzymes, and high vial load.
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Key points
Severe fever with thrombocytopenia syndrome is a severe
hemorrhagic fever without effective treatment. Patients
from endemic areas with fever, thrombocytopenia, leuco-
penia, gastrointestinal symptoms, and central nervous sys-
tem manifestations should be considered as SFTS.
Background
Severe fever with thrombocytopenia syndrome (SFTS) is
an emerging hemorrhagic fever, which was first discov-
ered in rural areas of eastern and central China in 2009
[1] and more recently in South Korea and Japan [2, 3].
SFTS is caused by a novel bunyavirus-SFTS virus that
has been detected from ticks and ticks are thought to be
the vector of SFTSV [1, 4].
The major clinical symptoms of SFTS patients in-
cluded acute fever (temperature of 38 °C or more),
thrombocytopenia, leucopenia, gastrointestinal symptoms,
and central nervous system (CNS) manifestations, followed
with multiple organ dysfunctions [5–8]. Some cases in crit-
ical condition had the following manifestations: disturbance
of consciousness, gastrointestinal bleeding, pulmonary
hemorrhage, and skin bruising. The cases died due to dif-
fuse intravascular coagulation (DIC), multiple organ failure,
and shock [7–9].
Previous studies have confirmed that the outcome of
the SFTS patients has been associated with the levels of
their clinical characters and the biochemical markers at
the early stage [5–8, 10]. As the fatality rate of this dis-
ease was surprisingly high and the main risk factor for
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this phenomenon was not clear, this study was designed
to analyze the relationship between various factors and
the outcome of the SFTS patients through meta-analysis
and to predict the severity of the disease.
Methods
Search strategy
We searched Web of Science, PubMed, Wan Fang Data,
and Chinese National Knowledge Infrastructure data-
bases from 2009 to 2016 using the following terms:
(“SFTS” OR “SFTSV”) and “patient”. Moreover, we not
only identified articles through database retrieval, but
also by reviewing the reference list of retrieved articles
to search for further relevant documents.
Inclusion and exclusion criteria
Articles included in this meta-analysis had to meet the
following criteria: the first and foremost, the SFTS pa-
tient mentioned in the selected studies must be con-
firmed as meeting one or more of the following criteria:
(1) isolated the virus from the patient’s samples, (2)
SFTSV RNA was detected from the patient’s serum by a
quantitative reverse-transcriptase polymerase chain reac-
tion (qRT-PCR) and (3) a 4-fold or greater increase of
antibody titers was detected between a paired serum
samples of the patient collected from the acute and con-
valescent phases of infection; Secondly, the article con-
tained the most recent or largest population was selected
when the studies using the same or overlapping data by
the same authors. Exclusion criteria included small scale
studies with fewer than 15 patients, works designated as
case reports, conference abstract, letters, editorials or
reviews, and duplicated publications.
Data extraction and quality assessment
Based on the aforementioned inclusion and exclusion
criteria, the preliminary screening was made by reading
the title and abstract of the literature. Then, after read-
ing the full text, the documents were eventually con-
firmed. All selected articles were independently screened
and evaluated by two reviewers. After cross-checking,
any disagreement was resolved by a third evaluator. The
following information was extracted from every eligible
article: the first author, year of publication, country,
number of patients, number of fatalities, and the positive
number of each clinical character.
Statistical analysis
I-squared was chosen to reflect the heterogeneity among
studies. Values of p < 0.05 and I-squared >50% were con-
sidered to be statistically significant. According to the re-
sult of heterogeneity, the proper model was adopted to
merge the clinical parameters of the patients: When the
data were homogeneous, the fixed effect mode was used
and for heterogeneous data, the random effect model
was employed. Publication bias was assessed by using
Egger’s test: p < 0.05 was considered to be statistically
significant. For each selected publication, the pooled fa-
tality rate, pooled positive rate of each clinical character,
and their 95% confidence intervals (CI) were calculated.
We also calculated simple pooled rates along with a
naive weighted average method [11]. All analyses were
performed with STATA 12.0 (Stata Corp LP, College
Station, Texas, United States).
Results
Literature search
A total of 241 relevant articles were retrieved after the
preliminary screening from the electronic databases and
other sources. Two hundred one of these literatures
were excluded after review of the title and abstract for
irrelevant topics, and an additional six documents were
removed for duplication of the data. After reading the
full text of the remaining 34 articles, 25 articles were ex-
cluded due to lack of some indicators. Nine studies were
included for further meta-analysis. The data from these
studies included in the meta-analysis was shown in
Table 1.
Basic information description
A total of nine articles were included in this study. From
the nine eligible studies, a total of 844 patients were in-
cluded in this meta-analysis, which were published from
2011 to 2015. All the individuals were laboratory-
confirmed as SFTS patients. In all SFTS patients, the
proportion of female was 48.1%. The patients ranged
from 7 to 89 years of age and most of them (80%) were
over 50 years old. Ninety-two percent of the patients
were farmers living in wooded and hilly areas and working
in the fields before onset of the disease. Most confirmed
SFTS patients (96%) involved in this analysis were admit-
ted to the hospital from May to October.
Table 1 Summary of the studies included in the meta-analysis
Reference number Author Publication year Country Samples
[1] Yu et al. 2011 China 154
[5] Deng et al. 2013 China 115
[6] Gai et al. 2012 China 59
[7] Sun et al. 2012 China 59
[8] Ding et al. 2014 China 59
[9] Liu et al. 2013 China 311
[10] Zhang et al. 2012 China 49
[32] Cui et al. 2013 China 16
[33] Wen et al. 2014 China 22
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The case fatality rate and clinical character of SFTS patients
The forest plot of case fatality rate of SFTS patients was
shown in Fig. 1. The pooled case fatality rate was 16%
(95% CI: 0.13–0.19). By heterogeneity analysis, I-squared
of case fatality rate was 10.6% (p = 0.348), implying that
there was no significant heterogeneity among the samples.
The pooled positive rates of clinical characters are
shown in Table 2. As the definition of ‘fever’ was different
in various studies, the heterogeneity of pooled positive rate
of fever was 85.2% (p < 0.05), it was recommended to
choose the simple pooled rate to describe the situation of
fever in SFTS patients. The simple pooled positive rate of
fever was 94%. As the I-squared of pooled rate of
thrombocytopenia was 71% (p = 0.03), we chose the simple
pooled rate to reflect the combined effects. Symptomatic
patients comprised 65% of the group. All the studies have
defined ‘leucopenia’ as leukocyte count <4.0 × 109/L, and
88% of patients presented with this laboratory finding. Pa-
tients with SFTSV infection usually have gastrointestinal
symptoms, including anorexia, nausea, vomiting, diarrhea
or abdominal pain. The polled positive rate of those
symptoms were 83%, 54%, 39%, 34%, 22%, respectively.
In addition, patients with SFTSV infection also had
hemorrhagic manifestations and central nervous system
manifestations (Table 2).
Laboratory parameters of SFTS patients
During the early stage of SFTSV infection, the serum
viral load was high both in non-fatal and fatal patients.
Nevertheless, along with the development of the disease,
the serum viral load decreased in non-fatal patients, but
still remained at a high level in fatal cases. All the selected
literatures showed that SFTSV infection was associated
with liver and kidney function impairment. Laboratory
examination found an increase of serum enzymes, such as
aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), lactate dehydrogenase (LDH), creatine kinase
(CK), as well as creatine kinase MB fraction (CK-MB),
which indicated the liver dysfunction. The level of serum
enzymes increased to a peak about 10 days after onset in
non-fatal SFTS cases, and then gradually declined to nor-
mal level, however, it progressively increased in fatal cases.
Similar to the above findings, blood urea nitrogen (BUN)
also increased in SFTS patients, which is a parameter that
can indicate impairment of renal function. Furthermore,
in all detected clinical laboratory parameters, blood coagu-
lation times (activated partial thromboplastin time, APTT
and thrombin time, TT) were longer among SFTS patients
than the healthy individuals. In addition, cytokine levels,
such as interleukin-6 (IL–6), IL-8, IL-10, granulocyte col-
ony-stimulating factor (G-CSF), and interferon-γ (IFN-γ)
were enhanced in SFTS patients and were significantly
higher in fatal cases than the non-fatal individuals.
Discussion
Most cases are farmers (92%), who were living or working
in wooded and hill areas, where ticks were commonly
found. This phenomenon indicated that ticks are most
Fig. 1 Forest plot of case fatality rate for SFTS patients. The point estimates from each study were shown as solid squares. The pooled estimates
were shown as an empty diamond. Error bars represented 95% CIs. (Reference No. [32] and No. [33] were excluded because they did not
mention the fatality rate)
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likely to be the vector of SFTSV [1, 4, 12]. Most patients
were admitted to hospital from May to October. During
this period, farmers were engaged in the agricultural activ-
ities, and were easily exposed to ticks. This interpretation
indirectly confirmed that ticks are the vector of SFTSV. In
addition, it has been confirmed that SFTSV can be trans-
mitted to humans by contact with blood or body fluid
from SFTS patients [13, 14]. Therefore, individuals should
not only pay attention to reduce exposure to ticks in daily
life, but also pay attention to personal protection when
they take care of SFTS patients.
The disease mainly occurs in the elderly population
[15, 16]. Consistent with the aforementioned results, in
this study, the vast majority of the patients are over
50 years old. Studies revealed that older age was a sig-
nificant risk factor for fatal outcome of SFTS patients
[8, 9, 17, 18]. The cause of this phenomenon-older pa-
tients tended to have more severe symptoms, is likely
to be that the older people have lower immunological
capacity to limit the replication of SFTSV. The high in-
cidence of SFTS in old people could be caused by a
population skew toward to old people in countryside
because many young people left rural area to work in
city. However, a previous study indicated the SFTSV
antibody positive rate was not significantly different
among people at different age groups in rural area, sug-
gesting that age is the critical risk factor to determine
for SFTS morbidity and mortality [19].
The typical features of SFTS are acute fever and
thrombocytopenia. About 94% of patients had acute
fever at the early stage and most of them returned to
normal in 10 days. At the early stage of infection, as ex-
ogenous stimuli, the virus activated the body to release
endogenous pyrogens. Endogenous pyrogens, in turn,
circulate to the thermoregulatory center of the brain
where it cause an elevation of the body temperature
[20]. Over 65% of patients had a lower platelet count
(platelet count <150 × 109/L). Both in vitro and in vivo
assays confirmed that the virus adhered to platelets and
facilitated the phagocytosis of platelets by macrophages
[8, 21]. Those patients with thrombocytopenia often
accompanied with hemorrhagic tendency, such as pe-
techiae and microscopic hematuria. In addition, severe
hemorrhagic symptoms, such as gastrointestinal bleeding,
macroscopic hematuria and hematoma, are commonly ob-
served in sever patients with disseminated intravascular
coagulation [3]. In comparison with SFTS patients who
survived, the deceased patients had a more serious
hemorrhagic tendency. It suggests that bleeding tendency
was associated with the death of SFTS patients.
The central nervous system symptoms commonly oc-
curred approximately 5 days after the onset of illness,
and persisted for 1–2 weeks [6]. The CNS manifestations
of SFTS patients included dizziness, headache, apathy
and coma before death. The CNS manifestations of
deceased patients were more serious than survivors in-
dicated that CNS manifestations are the risk factors
for the death of SFTS patients.
In SFTS patients’ serum, the levels of liver, kidney, and
cardiac enzymes are commonly dramatic elevated, indi-
cating the impairments of those organs. In survivors, the
serum enzymes reached to the maximum levels in about
10 days after infection, and then gradually declined to
the normal levels. However, in deceased patients, the
levels of serum enzymes appeared to progressively rise
and reached to the maximal values before death. The risk
analysis revealed that elevated AST, LDH, CK and CK-MB
were risk factors associated with severity among SFTS pa-
tients and fatality among severe SFTS patients [5, 6].
Levels of serum cytokines such as IL-6, IL-10, G-CSF,
and IFN-γ were increased in SFTSV-infected patients.
Clinical studies have indicated that cytokine storm, char-
acterized by overproduction of certain cytokines, is com-
monly associated with the severity of the disease [5, 7].
Consistent with the findings aforementioned, the virus
Table 2 The pooled positive rates of clinical charactersa
Pooled 95% CI Simple pooled
I2 (%) p Rate Low Up Rate
Feverb 85.20 <0.05 0.99 0.97 1.00 0.94
Leucopeniac 0.00 0.70 0.88 0.82 0.94 0.73
Thrombocytopeniad 71.00 0.03 0.83 0.51 1.16 0.65
Anorexia 58.70 0.09 0.83 0.76 0.91 0.85
Weakness 46.70 0.09 0.74 0.54 0.94 0.83
Nausea 34.60 0.21 0.54 0.49 0.60 0.55
Myalgias 49.60 0.09 0.51 0.42 0.60 0.62
Proteinuria 62.30 0.10 0.50 0.39 0.61 0.51
Lymphadenopathy 61.80 0.05 0.39 0.29 0.49 0.35
Vomiting 55.50 0.05 0.39 0.33 0.46 0.38
Joint pain 0.00 0.33 0.35 0.27 0.43 0.28
Chills 30.10 0.24 0.32 0.22 0.43 0.27
Diarrhea 66.60 0.02 0.31 0.23 0.39 0.34
Hematuria 25.10 0.25 0.29 0.22 0.36 0.29
Cough 67.60 0.08 0.28 0.20 0.36 0.26
Abdominal pain 26.80 0.25 0.22 0.15 0.29 0.29
Dizziness 0.00 0.53 0.20 0.16 0.24 0.25
Headache 19.80 0.29 0.17 0.13 0.21 0.22
Case fatality rate 10.60 0.35 0.16 0.13 0.19 0.16
Petechiae 16.70 0.31 0.08 0.06 0.11 0.11
aThe data would be excluded if it did not mention the corresponding
clinical character
bFever was defined as body temperature ≥38 °C in references [1, 5, 32, 33];
≥37.5 °C in references [8, 9]; ≥39 °C in reference [6]
cLeucopenia was defined as leukocyte count <4.0 × 109/L
dThrombocytopenia was defined as platelet count <150 × 109/L in references
[5, 32, 33]; <100 × 109/L in references [1, 8–10]
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infection including hemorrhagic fever virus, such as,
Crimean Congo Hemorrhagic Fever (CCHF), Ebola, and
Rift Valley fever virus can lead to cytokine storm which
is associated with the progression of the disease [22–24].
Cytokine storm occurring in the acute phase of the dis-
ease has been widely hypothesized to be the main cause
of morbidity and mortality for SFTSV infection [25].
Under normal circumstances, inflammatory cytokine and
chemokine could promote activation and chemoattraction
of lymphocytes and exert antiviral effects. However, recent
findings indicated that cytokine storm, characterized by an
overwhelming and imbalanced profile of cytokines, could
become excessive and harmful [26].
Serum viral load was considered to be the major la-
boratory marker for clinical diagnosis. After the onset of
the illness, the initial serum viral load was high in all pa-
tients. Then the virus was gradually cleared in survivors
at the recovery phase, but still remained high in the fatal
patients. There was a difference between the serum viral
load of the surviving and deceased patients [8, 27–29].
High serum viral load was considered to be the high risk
factor that resulted in the death of SFTS patients [10].
Therefore, it was identified as an important parameter
to predict the outcome of the SFTS patients. Meanwhile,
studies founded that there was a positive correlation
between the serum viral load and the levels of various
cytokines. In other words, during the acute phase of
SFTSV infection, the higher viral load, the higher levels
of cytokines (except for RANTES and PDGF-BB) [7, 28].
These findings suggested that the high viral load may lead
to excessive secretion of cytokines, which could further
aggravate the progression of the disease.
Ribavirin is reported to be effective for treating CCHF
infections and hemorrhagic fever with renal syndrome
[30, 31]. However, studies have found that intravenous
ribavirin had no effect on reducing the serum viral load
in SFTS patients [5, 9]. Meanwhile, the use of tetracycline
for the treatment in SFTS patients is not justified unless
co-infection can be confirmed [32]. In addition, treatment
of SFTS patients with corticosteroids for acute respiratory
distress syndrome is controversial. This is because though
corticosteroids can suppress the cytokine storm, it also
can increase the risk of developing critical disease from
viral infection [5]. Hence, supportive therapy is the most
essential and effective part of case management [33].
Our meta-analysis has some limitations: the primary
limitation of our meta-analysis was that there are subtle
differences in the definition of the clinical characters in
different studies. Since in different articles, the forms of
the laboratory parameters were not uniform, we could
not carry out a systematic analysis for these indicators.
Also, like most other meta-analysis, the overall findings
from the meta-analysis were limited by the quality of the
primary studies.
Conclusion
In conclusion, the major clinical characters of patients
with SFTSV infection were fever, thrombocytopenia,
leucopenia and gastrointestinal symptoms, and central
nervous system manifestations. The risk factors for sever-
ity and fatality among SFTS patients included: old age,
CNS manifestations, bleeding tendency, elevated serum
enzymes, and high vial load.
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